Publications
Detailed Information
Sunitinib in metastatic renal cell carcinoma: An ethnic Asian subpopulation analysis for safety and efficacy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Se-Hoon | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.contributor.author | Mainwaring, Paul | - |
dc.contributor.author | Ng, Christina | - |
dc.contributor.author | Chang, John W-C | - |
dc.contributor.author | Kwong, Philip | - |
dc.contributor.author | Li, Rubi K. | - |
dc.contributor.author | Sriuranpong, Virote | - |
dc.contributor.author | Toh, Chee-Keong | - |
dc.contributor.author | Yuan, Jinyu | - |
dc.contributor.author | Pitman Lowenthal, Susan | - |
dc.contributor.author | Chung, Hyun C. | - |
dc.date.accessioned | 2021-01-31T11:01:39Z | - |
dc.date.available | 2021-01-31T11:01:39Z | - |
dc.date.created | 2020-12-17 | - |
dc.date.issued | 2014-09 | - |
dc.identifier.citation | Asia-Pacific Journal of Clinical Oncology, Vol.10 No.3, pp.237-245 | - |
dc.identifier.issn | 1743-7555 | - |
dc.identifier.other | 119269 | - |
dc.identifier.uri | https://hdl.handle.net/10371/172974 | - |
dc.description.abstract | Aims: We evaluated and compared the safety and efficacy of sunitinib in Asian and non-Asian patients with metastatic renal cell carcinoma enrolled in a previously reported global expanded access program. Methods: Previously treated and treatment-naive patients received open-label sunitinib at a starting dose of 50 mg/day for 4 weeks, followed by 2 weeks off treatment, in repeated 6-week cycles. Safety was assessed regularly, tumor measurements were performed per local practice, and survival data collected where possible. Results: Data were available for 212 Asian patients from Asian sites (Asian-A), 113 Asian patients from non-Asian sites (Asian-O) and 4046 non-Asian patients. The most common grade 3/4 treatment-related adverse events were neutropenia, thrombocytopenia, hand-foot syndrome, diarrhea, asthenia and fatigue. The incidence of many adverse events was greater in Asian-A than in Asian-O or non-Asian patients. Sunitinib efficacy was comparable between Asian and non-Asian patients, with an objective response rate of 18% versus 14%; median progression-free survival of 8.7 versus 10.9 months; and overall survival of 18.9 versus 18.4 months, respectively. Conclusions: Sunitinib demonstrated tolerable safety and similar efficacy in Asian and non-Asian patients. Geographic differences in the reported frequency of specific adverse events were noted across Asian patients. | - |
dc.language | 영어 | - |
dc.publisher | Blackwell Pub. Asia | - |
dc.title | Sunitinib in metastatic renal cell carcinoma: An ethnic Asian subpopulation analysis for safety and efficacy | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 방영주 | - |
dc.identifier.doi | 10.1111/ajco.12163 | - |
dc.citation.journaltitle | Asia-Pacific Journal of Clinical Oncology | - |
dc.identifier.wosid | 000340544000006 | - |
dc.identifier.scopusid | 2-s2.0-84906242695 | - |
dc.citation.endpage | 245 | - |
dc.citation.number | 3 | - |
dc.citation.startpage | 237 | - |
dc.citation.volume | 10 | - |
dc.identifier.sci | 000340544000006 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | ENDOTHELIAL GROWTH-FACTOR | - |
dc.subject.keywordPlus | TYROSINE KINASE INHIBITOR | - |
dc.subject.keywordPlus | INTERFERON-ALPHA | - |
dc.subject.keywordPlus | JAPANESE PATIENTS | - |
dc.subject.keywordPlus | PHASE-II | - |
dc.subject.keywordPlus | IN-VIVO | - |
dc.subject.keywordPlus | SU11248 | - |
dc.subject.keywordPlus | TOXICITY | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordAuthor | Asian | - |
dc.subject.keywordAuthor | metastatic renal cell carcinoma | - |
dc.subject.keywordAuthor | sunitinib | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.